|Last Price$29.38||Day Change (%)-0.37%|
|Open Price$29.43||Day Change ($)-0.11|
|Day Range29.36–29.67||52-Week Range27.81–32.96|
As of Thu 08/28/2014 07:11 PM EST | USD
Progenics Pharmaceuticals PGNX and partner Wyeth WYE announced Thursday that both the Food and Drug Administration and the European Medicines Agency have accepted new drug applications for subcutaneous MNTX, which aims to treat postoperative ileus and opioid bowel dysfunction. We are leaving our ...
Recent deals have been driven more by tax strategies than therapeutic synergies.
Mallinckrodt Announces Key Leadership Appointments Following Completion of Questcor Acquisition
Grant & Eisenhofer Represents Whistleblowers in Nearly $100 Million Settlement With Community Health Systems, Resolving Claims that Medicare/Medicaid Payors Were Bilked by Excessive ER Admissions
Inside Clipper Fund's makeover.
We believe breakups could unlock value for big pharma shareholders.
ETFs provide a great means to gain exposure to this battered health-care giant.
Two veteran investors discuss the winners and losers of reform and where they're looking for future growth.